Dilafor announces continuous positive results from the phase 2b study on tafoxiparin

STOCKHOLM, SWEDEN 15 February 2023. Dilafor has finalized its phase 2b study with its drug candidate tafoxiparin. The purpose of this extended study was to study the efficacy of the drug candidate tafoxiparin at additional doses. The results show that the positive effect obtained in the phase 2b study persists in additional dosages. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. Up to 30 percent of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child resulting in high healthcare costs. The completed extension of the phase 2b study included a total of 164 women, and the results show that the effect persists at all doses included in the study. In addition, a clear dose-response relationship was registered. “The consistency of the study results reinforces the hypothesis that tafoxiparin has great potential to reduce the risks for both mother and child at planned start of labor. Tafoxiparin’s ability to maintain the effect at all of the evaluated doses that were included in the study is a sign of strength ahead of the drug candidate’s continued development,” says Lena Degling Wikingsson, CEO of Dilafor. For further information, please contact: Lena Degling Wikingsson, CEO, Dilafor AB Phone: +46 70 790 02 07 TO THE EDITORS About Dilafor AB Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. The company’s primary goal is to decrease the incidence of slow progress of labor both after induction of labor and after spontaneous onset of labor. The main owner of Dilafor is KDev Investments AB, which is jointly owned by Karolinska Development AB (publ) and Rosetta Capital IV. The other main owners are Opocrin S.P.A and the Foundation for Baltic and European Studies (Östersjöstiftelsen). For more information, please visit: www.dilafor.com About tafoxiparin Tafoxiparin is a proprietary heparan sulfate mimetic developed by Dilafor. At least 30% of all term pregnant women experience planned start of labor. Conventional treatments are associated with complications for both the mother and child. Tafoxiparin is developed as a new drug candidate for priming of labor i.e., remodeling of both the cervical and uterine tissue.

The release as fetched from its publisher. dilafor.com ↗